Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts

Breast Journal

Volumn 11, Issue 3, 2005, Pages 183-187

  Stark, Azadeh ^a,b   Lu, Mei ^b   Mackowiak, Patricia ^b   Linden, Michael ^b  

^a Josephine Ford Cancer Center   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Contralateral breast cancer; Estrogen receptor; HER 2 neu

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GAMMA UROGASTRONE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CELL PROLIFERATION; DATA BASE; DRUG EFFECT; DRUG INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD; PREVALENCE; PROTEIN EXPRESSION; TREATMENT OUTCOME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PREVALENCE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TAMOXIFEN; UNITED STATES;

EID: 18644371592     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2005.21579.x     Document Type: Article

References (26)

1. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:855-61.
2. Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer 1998;34:2000-2009.
3. Bernstein JL, Lapinski RH, Thakore SS, Doucette J, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology 2003;14:552-58.
4. Li CI, Malone KE, Porter PL, Daling JR. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 2003;89:513-18.
5. Verhoog LC, Brekelmans CTM, Seynaeve C, Meijers-Heijboer EJ, Klikn JGM. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000;83:384-86.
6. Bernstein JL, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 1992;136:925-36.
7. Rutqvist LE, Cedermark B, Glass U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83:1299-306.
8. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2002;93:1008-13.
9. Kaas R, Peters JL, Hart AAM, Voogd AC, Rutgers EJT, van Leeuwen FE. The influence of tamoxifen treatment on the estrogen receptor in metachronous contralateral breast cancer. Br J Cancer 2003;88:707-10.
10. Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, et al. Pattern of hormone receptor status of secondary contralateral breast cancer in patients receiving adjuvant tamoxifen. Clin Cancer Res 2002;8:3427-32.
11. Samant RS, Olivotto IA, Jackson JS, Mates D. Diagnosis of metachronous contralateral breast cancer. Breast J 2003;7:408-10.
12. Fisher B, Costantiono JP, Wickerman DL, National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: a report of the National Surgical Adjuvant Breast and Bowel Project P-I. J Natl Cancer Inst 1998;90:1371-88.
13. Freedman AN, Graubord BK, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer prevention. J Natl Cancer Inst 2003;95:526-32.
14. Lagerlund M, Hedin A, Sparen P, et al. Attitudes, beliefs, and knowledge as predictors of non-attendance in a Swedish population-based mammography screening program. Prev Med 2000;31:417-28.
15. Lerman C, Rimer B, Trock B, et al. Factors associated with repeat adherence to breast cancer screening. Prev Med 1990;19:279-90.
16. Lee JRJ, Vogel VG. Who uses screening mammography regularly? Cancer Epidemiol Biomarkers Prev 1995;4:901-6.
17. Kaplan SH, Greenfield S, Ware JE Jr. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care 1989;27(3 suppl):S110-27.
18. Levinson W, Chaumeton N. Communication between surgeons and patients in routine office visits. Surgery 1999;125:127-34.
19. Jackson P, Teasdale J, Cowen PN. Development and validation of a sensitive immunohistochemical oestrogen receptor assay for use on archival breast cancer tissue. Histochemistry 1989;92:149-52.
20. Andersen J. Determination of estrogen receptors in paraffin-embedded tissue. Techniques and the value in breast cancer treatment. Acta Oncol 1992;1:611-27.
21. Wilbur DC, Willis J, Mooney RA, Fallon MA, Moynes R, di Sant' Agnes PA. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with dextran-coated charcoal assay. Mod Pathol 1992;5:79-84.
22. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-89.
23. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994;31:41-52.
24. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
25. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H. Amplification of HER-2/neu gene in HER-2/neu-overexpressing and nonoverexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15:116-24.
26. Stark A, Hulka BS, Joens S, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000;18:267-74.